Perspective

TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease

David A. Hicks*

In this perspective article, I will discuss our recent publication (Hicks et al., 2020), specifically its major findings and integration with the published literature. Alzheimer’s disease (AD) is a progressive neurodegenerative disease of predominantly unknown aetiology. Its neuropathological hallmarks are extracellular plaques formed of the amyloid beta (Aβ) peptide and neurofibrillary tangles of tau protein. Aβ peptides (Aβ_{1–40} and Aβ_{1–42}, are considered the most important) are generated by sequential proteolysis of the amyloid precursor protein (APP). This proteolysis can take one of two pathways: the nonamyloidogenic or amyloidogenic (Fig. 1A). The former is mediated by β-secretase, predominantly a disintegrin and metalloprotease domain-containing 10 (ADAM10) and the γ-secretase complex. This pathway releases the APP ectodomain as sAPPα, but crucially, results in cleavage of APP within the Aβ region, abrogating its generation. However, the amyloidogenic pathway is mediated by β-site APP cleaving enzyme 1 (BACE1, also known as β-secretase) and the γ-secretase complex, which results in the generation of Aβ species and the amyloid precursor protein intracellular domain. The amyloid precursor protein intracellular domain (AICD) has been shown to traffic to the nucleus where it can act as a transcriptional modifier. Although there are other minor APP secretases, those outlined herein represent the most significant. Alterations in APP processing have been linked to AD, insofar as the Aβ_{1–42}/Aβ_{1–40} ratio is increased in the disease (Andrew et al., 2016).

Over the last several years, transactive response DNA-binding protein 43 (TDP-43) has been linked to AD (Josephs et al., 2016). TDP-43 is a nuclear acid binding protein, which has a predominantly nuclear localization under physiological conditions (Budini and Buratti, 2011). However, the formation of cytoplasmic inclusions of TDP-43 has been associated with several neurodegenerative disorders (Gao et al., 2018). These inclusions have been found in the brains of individuals with AD and their presence correlates inversely with cognitive performance (Josephs et al., 2016). In addition, a recent study has linked TDP-43 pathology in AD to the APOE ε4 allele. This study found a significant association between APOE genotype and TDP-43 proteinopathy stage. TDP-43 burden was found to be significantly correlated with the APOE ε4 allele (Yang et al., 2018). Although there is a multitude of neuropathological evidence linking TDP-43 to AD, mechanistic understanding is sparse. This refers to the direct effects exerted by TDP-43, which may initiate or potentiate AD pathology. These direct roles of TDP-43 in AD include dysfunction in mitochondria, RNA splicing, axonal transport, stress granules and protein quality control (Gao et al., 2018). This definition therefore excludes suggested roles of TDP-43 in AD, which may be secondary effects of, for example, neuroinflammation. Thus, our study sought to investigate putative links between TDP-43 and APP processing in the context of AD (Hicks et al., 2020).

Localization of TDP-43 and APP in neurons: Initially, we examined the possible co-localization of TDP-43 and APP to assess a possible direct interaction. Immunocytochemistry in human neurons (i.e. derived from induced pluripotent stem cells) confirmed a nuclear localization of TDP-43, but this was in complete opposition to AICD immunoreactivity. Further immunocytochemistry and pharmacological treatment revealed AICD was localized to nucleoli, from which TDP-43 was excluded. Overall, this suggested that TDP-43 and APP do not interact directly.

Effects of APP expression on TDP-43: We subsequently assessed whether the APP holoprotein could modulate TDP-43 expression. This was performed by overexpressing each of the isoforms of APP (APP_{695}, APP_{751} and APP_{770}) and analyzing the effects on TDP-43 expression. We also targeted APP using siRNA and found that neither over-expression nor knockdown of APP had a significant effect on TDP-43 expression.

Modulation of TDP-43 expression and effect on APP metabolism: TDP-43 is known to regulate its own expression via its 3'UTR (Budini and Buratti, 2011), presenting a challenge in generating an over-expression model. To address this, we generated a doxycycline-responsive inducible system, using this model. To address this, we generated a doxycycline-responsive inducible system, whereby TDP-43-FLAG was expressed upon doxycycline treatment. Using this system, TDP-43 was over-expressed and its ability to modulate APP processing was investigated. Initially, this involved immunoblot analysis of the APP holoprotein, ADAM10, BACE1 and the γ-secretase components (presenilin 1, presenilin 2, nicastrin and Pen2). Taken together, TDP-43 overexpression did not affect the immunoreactivity of any of these target proteins. This showed that TDP-43 does not modulate APP processing at the level of protein expression. Further work focused on the amyloidogenic processing pathway. Doxycycline-induced TDP-43 over-expression did not affect BACE1 mRNA levels or activity, nor did it alter levels of either Aβ_{1–40} or Aβ_{1–42}.

Role of TDP-43 in AD: Beyond a modest number of gene mutations, the aetiology of AD is unknown. Thus, novel avenues of investigation, such as TDP-43, are particularly important. Several years of research findings have reported on the deleterious effects of TDP-43 inclusions in AD, but there has been a notable absence of detailed mechanistic understanding. It has been suggested that TDP-43 may influence BACE1 expression (Herman et al., 2012), although this was in the context of increased TDP-43 induced neuroinflammation. This makes it difficult to delineate the effects of TDP-43 from those of generalized inflammation. Our work in cultured cells suggests that TDP-43 does not modulate either expression of or processing of APP (Hicks et al., 2020). Overall, this illuminates a general confounding feature of mouse models when compared to cultured human cells. Although the presence of non-neuronal cells in mouse models can be advantageous given their importance in brain function and dysfunction, these cells can obscure effects in neurons. Cell stress (such as over-expression of TDP-43) may activate microglia, resulting in downstream effects in neurons. In mouse models, its consequently difficult to separate the direct effects of stress on neurons and the indirect effects mediated by non-neuronal cells. Our findings align with the finding that TDP-43 pathology is regionally disparate from the canonical amyloid pathology of AD (Josephs et al., 2016). Taken together, these data suggest that TDP-43 and Aβ may represent twin, non-overlapping pathologies in AD. Were this to be the case, it would strengthen the growing case for multiple therapeutic interventions to target different pathological elements of the disease. For example, recent γ-secretase or α-secretase targeting interventions have not proved successful in clinical trials. This may be because a substantial number of individuals with AD also have TDP-43 pathology, which is not addressed by amyloid-focused therapies.

Mitochondrial dysfunction: Recently, more information has started to emerge about the possible pathological effects of TDP-43 in AD. This has mainly, but not exclusively focused on putative deleterious effects on mitochondrial dysfunction. Although TDP-43 has a predominantly nuclear localization, it is also associated with mitochondria, acting to regulate endoplasmic reticulum mitochondrial tethering as well as mitochondrial mRNA transport and protein translation. Furthermore, TDP-43 may be involved in mitochondrial fission/fusion and trafficking such that any disturbance in TDP-43 function could negatively impact on any of these key features of mitochondrial activity (Gao et al., 2018). Recently, an inhibitory peptide has been shown to rescue mitochondrial dysfunction in AD transgenic mouse model (Gao et al., 2020). This represents an early example of a possible TDP-43 centric therapy, which may be used in combination with more traditional amyloid-focused approaches.

Axonal transport: As mentioned, TDP-43 is associated with mitochondrial transport and this process along axons is disturbed in AD. However, dysfunction in TDP-43 axonal transport has also been associated with reduced trafficking of mRNA-containing TDP-43 granules. This may be linked to the role of TDP-43 in delivery of mRNAs for dendritic local translation (Gao et al., 2018). Taken together, these data suggest that reduced TDP-43 function in AD may lead to reduced mitochondrial and mRNA granule trafficking.

Stress granules: The characteristic TDP-43 inclusions seen in AD have also been associated with stress granules (SGs), although the precise relationship is unclear. SGs are formed in response to stress to repress translation of non-essential proteins. Some reports have suggested that SGs can potentiate TDP-43 aggregation, or that TDP-43 contributes to
SG formation and slows their disassembly. However, the full role of TDP-43 in such stress response pathways remains to be elucidated (Gao et al., 2018).

Protein quality control: Recent data suggest that cytoplasmic TDP-43 aggregations may lead to impairment in the ubiquitin-proteasome system and this is dependent on protein tyrosine kinase 2. Protein tyrosine kinase 2 phosphorylates and activates TBK1, which then phosphorylates p62/SQSTM1, reducing the efficiency of protein aggregate transfer to the autophagosome (Lee et al., 2019). Interestingly, p62/SQSTM1 has been cited as a bridge between the ubiquitin-proteasome system and autophagy. A direct interaction of TDP-43 with p62/SQSTM1 has been reported, which is disturbed in some cases of frontotemporal lobar degeneration (Gao et al., 2018).

RNA splicing: A general increase in cryptic exon incorporation has been demonstrated in AD brains and associated with TDP-43 dysfunction (Sun et al., 2017). A recent report showed dual phosphomimetic mutations in TDP-43 (T153E, Y155E) reduced splicing ability and binding affinity for A(UG) 6 RNA (Li et al., 2017). In the context of AD, TDP-43 has been shown to regulate the splicing of tau, promoting exon 10 incorporation has been demonstrated in AD (Gao et al., 2018).

Conclusion: Thus, going forward, there is an urgent need to understand the precise role of TDP-43 in AD. For example, the presence of TDP-43 inclusions is a hallmark of motor neuron disease and, to a lesser extent, frontotemporal dementia. Given the low level of gene mutations driving TDP-43 pathology in motor neuron disease or AD (Ling et al., 2013), it is possible that similar processes lead to cytoplasmic TDP-43 accumulation in both diseases. However, this leads to the question of why such different neuronal populations are affected in the two diseases. In addition, AD can be present with or without TDP-43 pathology in relatively equivalent case numbers. This may be explained by a trigger which leads to AB and tau pathology. Then, in some individuals, a second “hit” could lead to aberrant accumulation of cytoplasmic TDP-43. This would go some way to explaining the worse cognitive performance of individuals with AD and TDP-43 pathology, compared to those without TDP-43 pathology. Indeed, a “two-hit” hypothesis has been discussed in the context of AD for some time. Several recent reports have revealed several putative roles for TDP-43 in AD, both in the context of loss of function and toxic gain of function, for example, through formation of cytoplasmic inclusions. Although TDP-43 has been linked to many cellular functions, this article is limited to those for which TDP-43 has a direct, AD-linked role. At the current time, mitochondrial function, axonal transport, protein quality control, stress granules and RNA splicing are key areas of investigation (Gao et al., 2018).

Overall, the data from our recent study (Hicks et al., 2020) show that, in vitro, TDP-43 does not modulate the expression of APP or its secretases (or components thereof). This suggests that the potential pathological effects of the cytoplasmic TDP-43 inclusions found in AD are distinct from those mediated by AB. Given the persistent pharmaceutical disappointments in this area, our findings suggest that failure to address TDP-43 pathology in AD may compromise the overall therapeutic strategy.

David A. Hicks*†
Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

*Current address: RBJ Online, Bourn Hall, Bourn, Cambridge, UK.

†Correspondence to: David A. Hicks, PhD, david.hicks.2@manchester.ac.uk.
https://orcid.org/0000-0001-6045-1063 (David A. Hicks)

References
Andrew RJ, Kellett KA, Thirakaran G, Hooper NM (2016) A Greek tragedy: the growing complexity of Alzheimer amyloid precursor protein proteinopathy. J Biol Chem 291:19235-19244.
Budini M, Buratti E (2011) TDP-43 autoregulation: implications for disease. J Mol Neurosci 45:473-479.
Gao I, Wang L, Gao C, Arakawa H, Perry G, Wang X (2020) TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic mouse model for Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis 1866:165580.
Gao I, Wang L, Huntley ML, Perry G, Wang X (2018) Pathomechanisms of TDP-43 in neurodegeneration. J Neurochem 146:7-20.
Herman AM, Khandelwal PI, Rebeck GW, Moussa CE (2012) Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lenti viral gene transfer models. Exp Neurology 235:297-305.
Hicks DA, Jones AC, Pickering-Brown SM, Hooper NM (2020) The cellular expression and proteolytic processing of the amyloid precursor protein in the context of TDP-43. J Biol Chem 291:19235-19244.
Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Lissner A, Petersen RC, Parisi JE, Dickson DW (2016) Updated TDP-43 in Alzheimer’s disease staging scheme. Acta Neuropathologica 131:571-585.
Lee S, Jeon YM, Cha SJ, Kim S, Kwon Y, Jo M, Jang YN, Lee S, Kim J, Kim SR, Lee KJ, Lee SB, Kim K, Kim Ju (2019) PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARD8P/TDP-43 proteinopathies. Autophagy 1-17.
Li W, Reeb AB, Lin B, Subramanian P, Foy EE, Knoverek CR, French RL, Bigio EH, Ayala YM (2017) Heat shock-induced phosphorylation of TAR DNA binding protein 43 (TDP-43) by MAPK/ERK kinase regulates TDP-43 function. J Biol Chem 292:5089-5100.
Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTLD: disrupted RNA and protein homeostasis. Neural Regeneration Research 8:416-438.
Sun M, Bell W, L’Alacri KD, Ling JP, Han H, Kageyama Y, Pletnikova O, Troncoso JC, Wong PC, Chen LL (2017) Cryptic exon incorporation in those with Alzheimer’s brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathologica 133:923-931.
Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, Bennett DA, Schneider JA, De Jager PL (2018) Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study. Lancet Neurol 17:773-781.

*Correspondence to: David A. Hicks, PhD, david.hicks.2@manchester.ac.uk.
https://orcid.org/0000-0001-6045-1063 (David A. Hicks)

Date of submission: May 14, 2020
Date of decision: June 21, 2020
Date of acceptance: September 7, 2020
Date of web publication: December 12, 2020

https://doi.org/10.4103/1673-5374.300983

How to cite this article: Hicks DA (2021) TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease. Neural Regen Res 16(7):1402-1403.

Copyright license agreement: The Copyright License Agreement has been signed by the author before publication.

Plagiarism check: Checked twice by iThenticate.
Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.